Literature DB >> 19283925

Pharmacology of antineoplastic medications in older cancer patients.

Lodovico Balducci1.   

Abstract

Older patients are more susceptible to the complications of chemotherapy, and may be less equipped to react to these complications. After an introduction to the basic principles of geriatric medicine, this article explores the treatment of older cancer patients with systemic chemotherapy, including discussions of the pharmacology of aging, the effectiveness and toxicity of antineoplastic treatment in this population, and issues that need to be addressed in future clinical trials.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19283925

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN： 0890-9091            Impact factor:   2.990


  4 in total

1.  Potential medication problems in older newly diagnosed cancer patients in Canada during cancer treatment: a prospective pilot cohort study.

Authors:  Martine T E Puts; Johanne Monette; Veronique Girre; Beatriz Costa-Lima; Christina Wolfson; Gerald Batist; Howard Bergman
Journal:  Drugs Aging       Date:  2010-07-01       Impact factor: 3.923

Review 2.  Factors influencing adherence to cancer treatment in older adults with cancer: a systematic review.

Authors:  M T E Puts; H A Tu; A Tourangeau; D Howell; M Fitch; E Springall; S M H Alibhai
Journal:  Ann Oncol       Date:  2013-11-26       Impact factor: 32.976

Review 3.  Falls in older adults with cancer: a systematic review of prevalence, injurious falls, and impact on cancer treatment.

Authors:  Schroder Sattar; Shabbir M H Alibhai; Sandra L Spoelstra; Rouhi Fazelzad; Martine T E Puts
Journal:  Support Care Cancer       Date:  2016-07-22       Impact factor: 3.603

4.  Prognostic Impact of Age at the Time of Diagnosis in Korean Patients with Diffuse Large B-cell Lymphoma in the Rituximab Era: A Single Institution Study.

Authors:  Hee Sang Hwang; Meejeong Kim; Chan-Sik Park; Dok Hyun Yoon; Cheolwon Suh; Jooryung Huh; Heounjeong Go
Journal:  Cancer Res Treat       Date:  2020-09-15       Impact factor: 4.679
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.